Affordable Access

Studies of catecholamine metabolism in schizophrenia/psychosis--I.

Authors
  • Maas, J W
  • Contreras, S A
  • Miller, A L
  • Berman, N
  • Bowden, C L
  • Javors, M A
  • Seleshi, E
  • Weintraub, S
Type
Published Article
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Publication Date
Feb 01, 1993
Volume
8
Issue
2
Pages
97–109
Identifiers
PMID: 8471132
Source
Medline
License
Unknown

Abstract

Acutely psychotic schizophrenic patients not taking antipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured in plasma, urine, and cerebrospinal fluid (CSF). Significant differences between patients and control subjects were more easily discerned during treatment with DBQ. In patients, HVA was increased in plasma but not in urine or CSF, although MHPG was increased in all three fluids. There were many significant correlations between plasma MHPG and HVA levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HVA correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients; disturbed NE metabolism may relate to negative symptoms as well.

Report this publication

Statistics

Seen <100 times